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Abstract
To identify early predictors of a severe or fulminant course in patients with acute viral hepatitis B (AVH-B). One hundred and thirty-eight
patients with symptomatic acute hepatitis B observed from 1999 to 2012 were enrolled. For each patient, the demographics, risk factors for
the acquisition of hepatitis B virus (HBV) infection, clinical, biochemical and virological data (HBV DNA, HBV DNA sequences) were
recorded and analysed. The HBV mutants in the polymerase region were sought in 110 (87%) patients by direct sequencing, and the
rtM204V/I mutations also by an allele-specific PCR. AVH-B was severe in 13 (9.4%) of the 138 patients enrolled, fulminant in 6 (4.3%) and
with a normal clinical course in 119. The 19 patients with severe or fulminant AVH-B more frequently than the 119 with a normal course
stated intravenous drug use (63.2% versus 36.1%, p 0.04) and were HBV-DNA negative (31.6% versus 11.8%, p 0.03) and anti-hepatitis C
virus (HCV) positive (57.9% versus 19.3%, p 0.0008); the prevalences of different HBV genotypes and of the rtM204V/I mutant were similar
in these three forms of AVH-B. A multivariate logistic regression analysis identified a pre-existing HCV chronic infection as the only factor
independently associated with a severe or fulminant clinical course of AVH-B (OR 4.89, 95% CI 1.5–15.94, p 0.01). A pre-existing HCV
chronic infection was identified as the only factor independently associated with a severe clinical presentation of acute hepatitis B, an
association most probably due to the combination of the liver lesions caused by acute hepatitis B and the pre-existing histological
abnormalities related to HCV chronic infection.
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Introduction
The clinical presentation associated with the hepatitis B virus
(HBV) acute infection varies according to the grade of reactivity
of cell-mediated immunity: low or absent in newborn babies and
infants, who frequently present an asymptomatic infection,
moderate in children aged under 12 years, who frequently
develop an asymptomatic or mild acute hepatitis, normal or high
in children aged over 12 years and in adults, most of whom
show symptomatic acute viral hepatitis B (AVH-B) [1,2]. An
over-reaction of the immune system leads to fulminant hepatitis
in nearly 1% of the cases [3], a clinical form of AVH-B with a very
high fatality rate that requires liver transplantation in the
majority of cases. Progression to chronicity decreases with the
increase in age, occurring in nearly 90% of newborn babies, in
10–40% of children, in nearly 5% of young adults and in 2% of the
older population [1].
The improvement in socio-economic and hygiene condi-
tions, the implementation of mass immunization programmes
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and the routine screening of blood donors have led to a
reduction in the incidence of AVH-B in the younger population
in western countries [4]. In these areas AVH-B infection is
most frequently acquired by non-vaccinated adults through
promiscuous unsafe sexual intercourse or injection drug use
[5], associated with a high probability of a symptomatic clinical
presentation that is sometimes severe and seldom life
threatening [6].
Old studies identified being female or being a young adult as
risk factors for a more severe clinical presentation [1,7]. More
recent investigations identified some virological factors influ-
encing the clinical presentation and course of AVH-B [8–11]:
HBV genotype D, described in the USA with a rate in patients
with a fulminant course that is double the rate in those with a
normal course [8]; the subgenotype B1/Bj, frequently identified
in the fulminant form in Japan and the G1896A mutation and
serum HBV DNA >5.23 log copies/mL, identified as indepen-
dently associated with a fulminant course [10]; and the
rtM204V/I variant found to be associated with severe acute
hepatitis B in Italy [11]. In addition, HBV genotype A was found
to be independently associated with a prolonged course of the
illness and with progression to chronicity [12,13]. Also certain
lifestyle factors (alcohol intake, drug use) and environmental
factors (concomitant hepatitis C virus infection) have been
associated with a more severe clinical course of AVH-B
[14,15]. Nevertheless, factors inducing a severe clinical
presentation and an unfavourable outcome are not fully
understood and further investigation is needed.
The present study was performed on 138 consecutive
patients with AVH-B and the aim was to identify early
predictors of a severe or fulminant course.
Patients and Methods
Patients
One hundred and thirty-eight consecutive patients with
symptomatic AVH-B were enrolled at one of the two
participating Units of Infectious Diseases from September
1999 to December 2012. These two Units, one in Naples and
one in Caserta, had been using the same clinical and laboratory
approach for years and had cooperated in several clinical
investigations [16–18].
All patients had detectable serum hepatitis B surface antigen
(HBsAg) and IgM to hepatitis B core antigen (anti-HBc IgM),
showed increased aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) serum values of at least ten
times the upper normal level, and lacked antibodies to hepatitis
D virus (anti-HDV) and to anti-human immunodeficiency virus
(HIV). Two patients with AVH-B observed in the same period,
one with HBV/HDV co-infection and one with HBV/HIV
co-infection, were not included in the present study. No
patient had been vaccinated against HBV. Ninety-two (66.7%)
patients had tested HBsAg negative in a screening performed
3–12 months before the onset of symptoms.
A questionnaire recording information on the demographics
and risk factors for acquiring HBV infection was completed by
each patient. A daily alcohol intake exceeding 30 g/day for
women and 40 g/day for men in the last 6 months or more
was defined as alcohol abuse; the patient’s statements
regarding intravenous drug addiction and alcohol abuse were
corroborated by the patient’s family and by serum/urine tests
in uncertain cases.
No patient received nucleos(t)ide analogue treatment
because at the time the study was performed these drugs
were licensed only for chronic hepatitis B in Italy.
Six patients with porto-systemic encephalopathy associated
with a rapid progressive reduction in prothrombin activity to
below 35% were considered to have developed fulminant
hepatitis [11,15]. Thirteen patients showed a severe clinical
presentation (severe hepatitis) characterized by the develop-
ment of ascites or by a progressive reduction in prothrombin
activity to below 35%, in the absence of porto-systemic
encephalopathy.
All procedures used were in accordance with the interna-
tional guidelines and with the Helsinki Declaration of 1975 and
revised in 1983. The study was approved by the Ethics
Committee of the Azienda Ospedaliera Universitaria of the
Second University of Naples, which oversees both participating
clinical centres. In addition, at the time of the first observation
all patients signed an informed consent for the collection and
storage of biological samples and for the anonymous use of
their data in clinical research.
For each patient a sample of plasma was obtained at the first
observation, stored at 40°C and never thawed until used for
this investigation.
A follow up of at least 6 months was planned and 120 (87%)
of the 138 patients enrolled in this study were followed up,
whereas 18 (13%) dropped out because of lack of compliance.
Patients were considered to have recovered from AVH-B if a
steady normalization of AST/ALT serum levels and HBsAg
serum clearance were achieved within 6 months from the
onset of symptoms; the persistence of HBsAg in serum for
more than 6 months was considered a sign of progression to
chronicity.
Clearance of HBsAg after the acute phase of the illness
confirmed the diagnosis of AVH-B in 118 patients, as this
serological event is unusual in patients with a reactivation of
HBV chronic infection. In addition, of the remaining 20
patients enrolled in this study, 16 had tested HBsAg negative
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3–12 months before the onset of symptoms and were found
to be HBsAg positive at hospitalization. Overall, the diagnosis
of acute hepatitis B was confirmed by changes in the HBsAg
serology in 134 (97.1%) of the 138 patients enrolled.
Routine methods
Hepatitis A virus (HAV), HBV, hepatitis C virus (HCV), HDV
and HIV serum markers were sought using commercial
immunoenzymatic assays (Abbott Laboratories, North Chi-
cago, IL, USA, for HBsAg, anti-HBs, anti-HBc (total and IgM),
anti-HAV (total and IgM) and anti-HIV 1 and 2; DiaSorin,
Saluggia, VC, Italy, for anti-HDV IgG and anti-HDV IgM; Ortho
Diagnostic Systems, Neckargemund, Germany, for anti-HCV).
Liver function tests were performed applying routine methods.
HBV molecular methods
Plasma samples of all patients were tested for HBV DNA, HBV
genotype and mutants in the polymerase region.
Plasma HBV DNA was sought by real-time PCR, as
previously described [19]; by this method, the detection
limit in plasma samples is estimated at around 40 IU/mL.
Hepatitis B virus genotypes were determined by phyloge-
netic analysis of sequences of 400 nucleotides of the S
region, as previously described [20]. The identification of
mutants in the polymerase region was performed by direct
sequencing of the region and by an allele-specific PCR
identifying the lamivudine-resistant strains 204V and 204I, as
previously described [11], which allowed the detection of
primary and compensatory mutations at a level of frequency
<5% of the viral population.
Hepatitis C virus genotyping was performed by a Line-
Probe-Assay (INNO-LIPA HCV II, Innogenetics, Zwigndrecht,
Belgium), which allows the identification of the six major
genotypes and their subtypes (1a, 1b, 2a/2c, 2b, 3a, 3b, 3c, 4a,
4b, 4c/4d, 4f, 4h, 5a and 6a), according to the classification
based on the amplification of the NS5 region of the HCV
genome. HCV RNA was quantified by performing a real-time
PCR in a Light cycler 1.5 (Roche Diagnostics, Branchburg, NJ,
USA); by this method, the detection limit in plasma samples is
estimated at around 40 IU/mL.
Statistical analysis
Continuous variables were summarized as mean and standard
deviation, and categorical variables as absolute and relative
frequencies. Differences in the mean were evaluated by an
unpaired Student’s t test, and the chi-squared test was applied
to categorical variables. Odds ratios, with 95% CI, were
estimated by a logistic regression model to evaluate the
relationship between severe acute hepatitis B and age, sex,
active intravenous drug use, alcohol intake, negativity for HBV
DNA at baseline and presence of HCV infection. A p value
<0.05 was considered to be statistically significant.
Results
The demographics and initial clinical, biochemical and virolog-
ical characteristics of the 138 patients with AVH-B are shown
in Table 1. The median age was 32 years (interquartile range
27–40) and males predominated (77.5%). A major risk factor
for the acquisition of HBV infection was identified in 87.7% of
the 138 patients investigated. Unsafe sexual activity and
intravenous drug use were the most frequent (40.6% and
39%, respectively) risk factors. Thirty-eight (27.5%) patients
had a history of alcohol abuse. The majority (74.6%) of patients
were infected by HBV genotype D (Table 1).
Thirty-four (24.6%) patients had been found to be
anti-HCV/HCV-RNA positive 12 months or more before the
onset of AVH-B, none of whom had undergone percutaneous
liver biopsy or a non-invasive evaluation of liver fibrosis, and all
of whom had become HCV-RNA negative by the onset of
AVH-B and remained so throughout the 6-month observation
period (Table 1).
TABLE 1. Demographics and initial characteristics of the
138 patients with acute viral hepatitis B
No. of cases 138
Age, years, Median (interquartile range) 32 (27–40)
Males, n (%) 107 (77.5)
Reporting a history of, n (%)
Unsafe homosexual contact 9 (6.5)
Unsafe heterosexual contact 47 (34.06)
IVDUa 55 (39)
Surgery 10 (7.2)
Declaring no risk factor 17 (12.3)
With alcohol abuse, n (%) 38 (27.5)
Days after the onset of symptoms, mean  SD 8.35  5.35
AST, IU/L, n.v. 15–35, mean  SD 1874.6  1059.7
ALT, IU/L, n.v. 15–35, mean  SD 2668.7  1226.85
Total bilirubin, mg/dL, mean  SD 15.6  8.8
Prothrombin activity, %, mean  SD 63.15  21.3
With severeb or fulminantc hepatitis, n (%) 19 (13.8)
HBV-DNA-negative patients, n (%) 20 (14.5)
HBV DNA, copies/mL, mean  SD 171 335 790  575 617 588
HBV genotype, n (%):
A 13 (9.4)
D 103 (74.6)
E 11 (8)
F 7 (5.1)
G 4 (2.9)
HBeAg, n (%):
Positive 62 (44.9)
Negative 76 (55.1)
rtM204V/I, n (%):
Positive 24 (17.4)
Negative 96 (69.7)
Data not available 18 (13.04)
HCV-Ab, n (%)
Positive 34 (24.6)
Negative 103 (74.6)
aIVDU, intravenous drug use.
bSevere hepatitis: development of ascites or of a progressive reduction in
prothrombin activity to below 35% in the absence of porto-systemic encephalop-
athy;
cFulminant hepatitis: porto-systemic encephalopathy associated with a rapid
progressive reduction in prothrombin activity to below 35%.
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The HBV polymerase region was explored in 110 (87%)
patients, as a plasma sample was no longer available for the
remaining 28. No nucleos(t)ide analogue-associated mutation
was identified by sequencing the polymerase region, but HBV
strains carrying the rtM204 substitution were detected in 24
(21.8%) patients by the allele-specific PCR assay (Table 1).
More precisely, 18 patients showed the rtM204V mutation,
five showed the rtM204I and one showed both the rtM204I
and rtM204V.
AVH-B was severe in 13 (9.4%) of the 138 patients enrolled,
and fulminant in six (4.3%) (Table 1). Of the 13 patients with
severe AVH-B, three developed ascites and ten developed a
progressive reduction in prothrombin activity to below 35%.
All of these 13 patients recovered and cleared HBV infection
during the follow up. Six patients developed porto-systemic
encephalopathy and showed a rapid reduction in prothrombin
activity to below 35%, indicating a fulminant course of the
illness. Of these six patients, three recovered, two underwent
successful liver transplantation and one died because no liver
was available for transplantation. Of the 119 patients with a
normal clinical course, 101 were followed up for at least
6 months and 34 were lost to follow up for lack of compliance.
Of the 101 patients, 99 (98%) recovered and cleared HBV
infection and two (2%) progressed to chronicity. Seroconver-
sion to anti-HBs was observed in 64 (64.6%) of the 99 patients
who recovered.
The differences in the initial characteristics between the 19
patients with severe or fulminant AVH-B and the 119 patients
with a normal clinical course are shown in Table 2. These two
groups were similar for age, prevalence of males and preva-
lence of patients with alcohol abuse. Compared with patients
with a normal clinical course, those with severe or fulminant
AVH-B were more frequently intravenous drug users (63.2%
versus 36.1%, p 0.04), showed significantly higher serum levels
of aminotransferases (AST, mean  SD: 3549  1786 IU/mL
versus 1667  862, p 0.001; ALT, mean  SD: 4306  2889
versus 2424  952, p 0.001) and of total bilirubin
(19.5  9.6 mg/dL versus 15  8.6, p 0.03) and were more
frequently HBV-DNA negative (p <0.05) (Table 2).
All six patients with fulminant hepatitis had an HBV DNA
load lower than 1 9 10E5 and were more frequently
HBV-DNA negative (66.7%) than the 119 patients with a
normal clinical course (11.8%, p <0.01) and the 13 with severe
AVH-B (15.4%, p 0.04) (Table 3).
TABLE 2. Comparative analysis of demographics and initial laboratory characteristics of the different clinical forms of acute viral
hepatitis B
Acute hepatitis B
Severea Fulminantb Severe and fulminant
With a normal
clinical course
Number of patients 13 6 19 119
Age, years, Median (interquartile range) 31 (27–39) 26 (25.5–33.5) 29 (25.5–39) 32 (27–40)
Males n (%) 12 (92.3) 4 (66.7) 16 (84)
Reporting a history of, n (%)
Unsafe homosexual contact 0 0 0 9 (7.6)
Unsafe heterosexual contact 2 (15.4) 3 (50) 5 (26.3) 42 (35.3)
IVDUc 9 (69.2) 3 (50) 12 (63.2) a 43 (36.1) b
Surgery 1 (7.8) 0 1 (5.3) 9 (7.6)
Declaring no risk factors 1 (7.8) 0 1 (5.3) 16 (13.4)
With alcohol abuse, n (%) 5 (38.4) 3 (50) 8 (42) 30 (25.2)
Days after onset of symptoms, mean  SD 7.5  5.2 9.3  3.7 7.8  4.8 8.4  5.4
AST, IU/L, n.v. 15–35, mean  SD 2938.6  1678.7 3963.2  164.6 3549  1786 c 1667.2  862.2 d
ALT, IU/L, n.v. 15–35, mean  SD 3684.1  2041.2 5332  4335.6 4306  2889 e 2423.6  951.9 f
Total bilirubin, mg/dL, mean  SD 18.9  10.4 21.8  7.2 19.5  9.6 15  8.,6
Prothrombin activity,%, mean  SD 37.1  15.9 23.8  12,6 35.7  15.9 68  18.4
HBV-DNA-negative patients, n (%) 2 (15.4) g 4 (66.7) h 6 (31.6) 14 (11.8)
HBV DNA, copies/mL, mean  SD 5.1E8  1.1E9 3E4  3E4 1.4E6  3.6E6 1.3E8  4E8
HBV genotype, n (%)
A 0 0 0 13 (10.9)
D 9 (69.2) 5 (83.3) 14 (73.7) 89 (74.8)
E 2 (15.4) 0 2 (10.5) 9 (7.6)
F 2 (15.4) 0 2 (10.5) 5 (4.2)
G 0 1 (16.7) 1 (5.3) 3 (2.5)
HBeAg, n (%)
Positive 4 (30.8) 2 (33.3) 6 (31.6) 56 (49.5)
Negative 9 (69.2) 4 (66.7) 13 (68.4) 63 (52.9)
rtM204V/I, n (%)
Positive 3 (23.1) 0 3 (15.8) 21 (17.6)
Negative 8 (61.5) 4 (66.7) 11 (57.9) 84 (70.6)
Datum not available 2 (15.4) 2 (33.3) 5 (26.3) 14 (11.8)
HCV-Ab, n (%)
Positive 7 (53.8) 4 (66.7) 11 (57.9) i 23 (19.3) l
Negative 6 (46.1) 2 (33.3) 8 (42.1) 96 (80.7)
aSevere hepatitis: development of ascites or a progressive reduction in prothrombin activity to below 35% in the absence of porto-systemic encephalopathy;
bFulminant hepatitis: porto-systemic encephalopathy associated with a rapid progressive reduction in prothrombin activity to below 35%,
cIVDU, intravenous drug use.
Differences significant to the statistical analysis: a vs. b: p 0.04; c vs d: p 0.001; e vs. f: p 0.001; g vs. h p 0.04; i vs. l: p 0.0008.
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The prevalence of patients with the rtM204V/I mutant
was similar in patients with severe or fulminant AVH-B and
in those with a normal clinical course (Table 2). Chronic
HCV infection was more frequent in the 19 patients with
severe or fulminant AVH-B (57.9%) than in those with a
normal course (19.3%, p 0.0008) (Table 2). Conversely,
severe or fulminant AVH-B occurred in one-third of the
anti-HCV-positive patients and in less than 8% of the
anti-HCV-negative patients. The multivariate logistic regres-
sion analysis identified a pre-existing HCV chronic infection
as the only factor independently associated with a severe or
fulminant clinical course of AVH-B (OR 4.89, 95% CI 1.5–
15.9, p 0.01) (Table 4).
Discussion
In the present study a pre-existing HCV chronic infection was
identified as the only factor independently associated with a
severe clinical presentation of AVH-B, an association most
probably due to the combined effect of the liver lesions caused
by AVH-B infection and the pre-existing histological abnor-
malities related to HCV chronic infection. Indeed, severe
or fulminant AVH-B was significantly more frequent in
anti-HCV-positive patients than in the anti-HCV-negative
patients, in full agreement with the data of our previous study
[15], which, however, did not investigate factors associated
with the severity of the clinical course of AVH-B.
All other presumed risk factors investigated in the present
study, that is, age, sex, history of intravenous drug use,
negative versus positive HBV DNA and a history of alcohol
abuse were not found to be independently associated with a
more severe clinical course, even though patients with severe
or fulminant AVH-B more frequently than those with a normal
clinical course had a history of intravenous drug use, alcohol
intake and an undetectable or low HBV load at baseline. In
other studies, the patients who died of fulminant hepatitis B
compared with those with less severe disease had had a
significantly more frequent exposure to alcohol, cocaine and
amphetamine [14,21,22], factors, however, not identified as
independently associated with a severe or fulminant course of
the disease.
Hepatitis B virus acute infection exerted a strong inhibition
of HCV chronic replication in patients who had been
anti-HCV/HCV-RNA positive 1 year or more before the
onset of AVH-B, as all of them were found to be HCV-RNA
negative/anti-HCV positive, both at their first observation after
the onset of symptoms of AVH-B and during the 6-month
follow up. These data are similar to those reported in our
previous study on a similar setting of patients, two-thirds of
whom became HCV-RNA positive during a 4- to 6-year follow
up and one-third of whom eradicated HCV chronic infection
[15], HCV clearance being significantly more frequent in
patients with severe AVH-B.
Several other models of superinfection or co-infection of
the human hepatitis viruses have been described: HCV
superinfection inhibits HBV replication in patients with HBV
chronic infection [23,24]; HAV superinfection impairs both
HBV and HCV replication in patients with a pre-existing
HBV or HCV chronic infection, respectively [25]; HDV
superinfection exerts a strong suppression of HBV chronic
replication [26], and a reciprocal viral inhibition has been
described in HBV/HCV concurrent acute infection, a model
of co-infection frequently characterized by the clearance of
HBV and the progression to chronicity of HCV infection
[27].
Also HBV/HCV or HBV/HDV/HCV chronic co-infections
are characterized by a reciprocal inhibition of viral replication
and by a more severe clinical presentation compared with
HBV or HCV chronic mono-infection [28]. A similar differ-
ence in the clinical presentation has been confirmed in a more
recent study on 1257 patients with chronic HCV infection
from New York City, which showed that liver fibrosis stage 3
or 4 was significantly more common in the 26 patients with
HBV-HCV dual infection than in 658 HCV-mono-infected
patients [29].
TABLE 3. Comparative analysis of hepatitis B virus (HBV) load at baseline in the different courses of the disease
Acute hepatitis B
Severea Fulminantb Severe and fulminant With a normal course
Number of patients 13 6 19 119
HBV-DNA-positive patients, n (%)
>10E7 copies/mL 5 (38.5) 0 5 (26.3) 35 (29.4)
1 9 10E6-1 9 10E7 copies/mL 4 (30.8) 0 4 (21.05) 22 (18.5)
1 9 10E5-1 9 10E6 copies/mL 0 0 0 16 (13.4)
1 9 10E4-1 9 10E5 copies/mL 2 (15.4) 1 (16.7) 3 (15.8) 21 (17.6)
<1 9 10E4 0 1 (16.7) 1 (5.3) 11 (9.2)
Negative 2 (15.4) a 4 (66.7) b 6 (31.6) c 14 (11.8) d
aSevere hepatitis: development of ascites or a progressive reduction in prothrombin activity to below 35% in the absence of porto-systemic encephalopathy;
bFulminant hepatitis: porto-systemic encephalopathy associated with a rapid progressive reduction in prothrombin activity to <35%,
Differences significant to the statistical analysis: a vs. b: p 0.01; c vs. d: p 0.03.
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AVH-B patients with an undetectable or low HBV DNA
serum level at the first observation should be closely
monitored for possible nucles(t)ide treatment as this virolog-
ical finding occurred more frequently in patients with fulminant
hepatitis than in those with a severe form of the disease, in
analogy with a previous observation showing a lower initial
HBV load in patients with fulminant hepatitis than in those with
a normal clinical course [30].
No patient in the present study was treated with nucleos(t)
ide analogues, as these drugs were not licensed for AVH-B in
Italy at the time severe or fulminant hepatitis occurred.
Current clinical practice advises the use of Tenofovir or
Entecavir, drugs of high potency and high genetic barriers, to
treat the more severe forms of AVH-B [31], a practice that
may reduce the mortality rate and/or the need for liver
transplantation [6,9,12].
The frequent occurrence of severe or fulminant AVH-B in
patients with HCV chronic infection should strongly urge the
physicians in care and the health authorities to extend HBV
vaccination to patients with HCV chronic infection. This
practice remains poorly applied worldwide, particularly in
developing countries where HCV chronic carriers are at a high
risk of HBV superinfection, despite being recommended by
several international and national guidelines and healthcare
institutions [31].
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